Background: Colorectal cancer (CRC) is the third most common cancer in Europe, with an
annual increase in incidence ranging between 0.4 and 3.6% in various countries. Although …

The BEBYP trial is a prospective, randomized, open-label, multicenter, phase III study
evaluating the continuation or reintroduction of bevacizumab with second-line …

Background. After a decade of extensive use, the actual contribution of bevacizumab in first-
line treatment of metastatic colorectal cancer (mCRC) is still unclear. Objective. To evaluate …

Background and Objectives: Colorectal cancer (CRC) is a leading cause of cancer-related
mortality and morbidity worldwide. Bevacizumab was approved for the treatment of …

Colorectal cancer (CRC) is among the most frequently diagnosed cancers and a major
cause of cancer‑related mortality worldwide. The aim of the present study was to determine …

Background. After approval of bevacizumab in Germany in 2005 for the treatment of
unresectable advanced or refractory colorectal cancer (CRC), this observational cohort …

The aim of the present study was to describe treatment outcomes for bevacizumab in
combination with chemotherapy based on data from the Czech registry of targeted therapies …

Introduction Retrospective data suggested that the continuation of BV with second line
chemotherapy (CT) beyond the progression to a first line treatment with BV was associated …

Background: Chemotherapy plus bevacizumab is a standard option for first-line treatment in
metastatic colorectal cancer patients. We assessed whether no continuation is non-inferior …

Background The CONCERT study (observational cohort study of patients with metastatic
colorectal cancer initiating chemotherapy in combination with bevacizumab) aimed to …